Omeros Corporation
1420 Fifth Avenue
Suite 2600
Seattle,
WA 98101
United States - Map
Phone: 206-676-5000
Fax: 206-676-5005
Web Site: http://www.omeros.com
| Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform, which is designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The companys lead PharmacoSurgery product candidate, OMS103HP, is in two Phase 3 clinical programs to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament reconstruction surgery, and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its product candidates also include OMS302 for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201 for use during urological surgery, including uroendoscopic procedures of the bladder, ureter, urethra, and other urinary tract structures. The companys pre-clinical developmental programs comprise MASP-2 program, in which it is developing antibody therapies to treat disorders caused by complement activated inflammation; cartilage protective program to treat cartilage disorders, such as osteoarthritis and rheumatoid arthritis; and Phosphodiesterase 10 program for the treatment of schizophrenia; GPCR program to treat a series of CNS disorders. Omeros Corporation was founded in 1994 and is based in Seattle, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Gregory A. Demopulos M.D., 50
Co-Founder, Chairman, Chief Exec. Officer, Managing Director, Pres, Chief Financial Officer Chief Medical Officer and Treasurer |
$
475.00K | N/A | Ms. Marcia S. Kelbon Esq., 49
VP of Patent, Sec. and Gen. Counsel |
$
285.00K | N/A | Dr. Pamela P. Palmer M.d. Ph.d.,
Co-Founder |
N/A
| N/A | Mr. David R. Toll , 41
Director of Fin. and Controller |
N/A
| N/A | Dr. Wayne R. Gombotz Ph.D., 49
VP of Pharmaceutical Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
0.0999 (1.42%) 
Profile
